Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at...
Medicaid
Final Sanction Removed at InnovAge Sacramento PACE Center Enabling New Participant Enrollment
DENVER, May 01, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare...
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+...
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Inovalon Expands Revenue Cycle Data Analytics Software to Support All EDI Clearinghouses for Healthcare Providers
SaaS Solution Delivers up to 93% First-Pass Yield and Prevents Revenue Leakage While Improving Cash Flow by up to 15%BOWIE,...
PersonalRX Acquires New York-Based Pharmacy
Expands high-touch, one-on-one approach to all patients in New York including MedicaidEAST RUTHERFORD, N.J., April 19, 2023 (GLOBE NEWSWIRE) --...
Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability
Net annualized savings from initiatives expected to be approximately $30 million beginning in 2024 FRANKLIN, Tenn., April 17, 2023 (GLOBE...
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settingsFRAMINGHAM, Mass., April 05, 2023 (GLOBE...
Milestone Scientific Provides 2022 Year-End Business Update
ROSELAND, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA
Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied...
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
BioStem Technologies Commends OIG’s Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider...
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent®(dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More...
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks...
MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
Company applauds the Office of Inspector General’s (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly...
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2022 Financial Results
Revenue increased 9.0% to $451.1 million, compared to Q4 2021 Gross margin increased 3.5% to $128.8 million, compared to Q4...